SciRhom, a Munich, Germany-based biopharmaceutical company developing therapeutic iRhom2 antibodies, raised EUR 63M in Series A funding.
The round was co-led by Andera Partners, Kurma Partners, Hadean Ventures, MIG Capital, and Wellington Partners, with participation from new investor Bayern Kapital and existing investors including High-Tech Gründerfonds (HTGF) and PhiFund Ventures from New York, USA.
In conjunction with this investment, Dr. Olivier Litzka from Andera Partners, Dr. Peter Neubeck from Kurma Partners, Dr. Georgina Askeland from Hadean Ventures, Dr. Fei Tian from MIG Capital and Dr. Varun Gupta from Wellington Partners will join SciRhom’s Board of Directors.
The company intends to use the funds to accelerate and broaden the impact of its therapeutic strategy in autoimmune disorders.
SciRhom offers proprietary iRhom2-targeting therapies and develops its lead antibody program SR-878 into and through clinical development. Based on positive preclinical data sets generated in vitro and in established animal models of rheumatoid arthritis (RA) and inflammatory bowel disease (IBD), the company has advanced its first program to a Phase 1-ready stage. As announced on June 12th, 2024, the first CTA approval was achieved paving the way for initiating a first clinical study in Austria in the second half of 2024. The study aims to evaluate safety in healthy volunteers and provide initial evidence of clinical activity in the second part of the study.
The leadership team includes:
- Dr. Jens Ruhe, Managing Director and COO,
- Dr. Jan Poth, Managing Director and CEO, and
- Dr. Matthias Schneider, CSO.
FinSMEs
09/07/2024